AstraZeneca/Ironwood Drug for IBS-C Passes China Phase III Test

AstraZeneca and Ironwood Pharma reported positive results from a global Phase III trial (including China) of linaclotide in patients suffering from irritable bowel syndrome with constipation (IBS-C). The drug met all primary and secondary endpoints in the trial. The two companies plan to file for CFDA approval of linaclotide in early 2016. AstraZeneca signed a $150 million deal with Ironwood in 2012 to share China regulatory and marketing responsibility for the drug, which Ironwood discovered. More details.... Stock Symbols: (NYSE: AZN) (NSDQ: IRWD) Share this with colleagues: // //